Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction
Michael D Miedema1, Jay N Cohn, Ross F Garberich
1University of Minnesota Cardiovascular Division, Minneapolis, MN 55407, USA. mied0007@umn.edu
Insights
Preventive medication use was low in ST-elevation myocardial infarction (STEMI) patients, even those with multiple cardiovascular risk factors and premature events. This highlights a gap in primary prevention strategies for coronary heart disease (CHD).
Area of Science:
- Cardiology
- Preventive Medicine
- Public Health
Background:
- Effective medications exist for primary prevention of coronary heart disease (CHD).
- Patient selection for preventive therapy remains a challenge, with many at-risk individuals not receiving treatment.
- This study addresses the gap in preventive care for individuals presenting with acute coronary events.
Purpose of the Study:
- To evaluate the utilization of preventive medications in patients experiencing ST-elevation myocardial infarction (STEMI).
- To assess the prevalence of cardiovascular risk factors in STEMI patients without prior known CHD.
- To identify disparities in preventive therapy use, particularly in younger patients with premature events.
Main Methods:
- Analysis of a prospective cohort of 1,710 STEMI patients.
- Data collected from a regional STEMI system database (May 2007 - July 2010).
- Inclusion of preadmission medication records and detailed patient demographics.
Main Results:
- Nearly 70% of STEMI patients analyzed had no prior diagnosis of CHD.
- Over 40% of these events were premature (men <55, women <65 years).
- Preventive medication use was low: aspirin (24.1%), statins (16.1%), and combination therapy (7.8%) in patients without known CHD, with even lower rates in premature events.
Conclusions:
- A significant proportion of STEMI patients lack prior CHD diagnosis and experience premature events.
- Despite numerous cardiovascular risk factors, the use of evidence-based preventive therapies is alarmingly low.
- Findings underscore the need to reassess and improve primary prevention strategies in acute coronary syndromes.
Background:
Multiple medications have proven efficacy for the primary prevention of coronary heart disease (CHD), but the appropriate patient population remains controversial. Even in the presence of multiple cardiovascular risk factors, many patients are not considered high risk and are not offered preventive medications despite proven efficacy.
Methods:
We analyzed a prospective cohort of 1,710 consecutive ST-elevation myocardial infarction (STEMI) patients treated in a regional STEMI system from May 2007 to July 2010 and enrolled in a comprehensive database that includes preadmission medications.
Results:
Of the 1,707 patients analyzed, 1,180 (69.1%) did not have known CHD before their event; and 482 (41.7%) of those patients had premature events (men <55 years old, women <65 years old). In patients without known CHD, cardiovascular risk factors were abundant (52.1% had hypertension, 43.6% had dyslipidemia, 41.4% had a family history of CHD, 58.5% were current or former smokers, and 14.9% were diabetic). Despite the high prevalence of risk factors, only 24.1% were on aspirin, 16.1% were on a statin, and only 7.8% were taking an aspirin and statin. Use of preventive medications was even less common in patients with premature events, including aspirin (15.2% vs 30.2%, P value < .001), statins (11.1% vs 19.5%, P value < .001), and the combination (5.6% vs 9.4%, P value < .001).
Conclusions:
Approximately 70% of a contemporary STEMI population did not have known CHD before their event, and >40% of those events would be considered premature. Despite the significant burden of cardiovascular risk factors, use of preventive therapy was alarmingly low in patients presenting with STEMI.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Acute Coronary Syndrome I: Introduction